Also found in: Dictionary.
Related to Namenda: Memantine, Exelon


Ebixa (CA) (UK), Namenda

Pharmacologic class: N-methyl-D-aspartate receptor antagonist (NMDA)

Therapeutic class: Anti-Alzheimer's agent

Pregnancy risk category B


Unclear. Thought to act as a low- to moderate-affinity NMDA receptor antagonist, binding to NMDA receptor-operated channels. (Activation of these channels is thought to contribute to Alzheimer's symptoms.)


Oral solution: 2 mg/ml

Tablets: 5 mg, 10 mg

Tablets (titration pack): 28 tablets of 5 mg and 21 tablets of 10 mg

Indications and dosages

Moderate to severe Alzheimer's-type dementia

Adults: Initially, 5 mg P.O. daily. Then titrate at intervals of at least 1 week in 5-mg increments, to a maximum of 10 mg P.O. b.i.d.

Dosage adjustment

• Moderate renal impairment


• Hypersensitivity to drug or its components


Use cautiously in:

• neurologic conditions, moderate to severe renal impairment, genitourinary conditions that increase pH

• pregnant or breastfeeding patients.


• Give with or without food.

Adverse reactions

CNS: dizziness, headache, syncope, aggressive reaction, confusion, somnolence, hallucinations, agitation, insomnia, vertigo, ataxia, abnormal gait, hypokinesia, anxiety, transient ischemic attack, cerebrovascular accident (CVA)

CV: hypertension, cardiac failure

EENT: cataract, conjunctivitis

GI: nausea, vomiting, diarrhea, constipation, anorexia

GU: frequent voiding, urinary incontinence, urinary tract infection

Hematologic: anemia

Musculoskeletal: back pain, arthralgia

Respiratory: cough, dyspnea, bronchitis, pneumonia

Skin: rash

Other: weight loss, fatigue, pain, falls, flulike symptoms, peripheral edema


Drug-drug. Cimetidine, hydrochlorothiazide, nicotine, quinidine, ranitidine, triamterene: altered blood levels of both drugs

Urine-alkalizing drugs (carbonic anhydrase inhibitors, sodium bicarbonate): decreased memantine elimination

Drug-diagnostic tests. Alkaline phosphatase: increased level

Patient monitoring

Check for heart failure and signs and symptoms of CVA.

• Monitor kidney function tests.

Patient teaching

• Tell patient to take with or without food.

• Instruct patient or caregiver not to mix solution with other liquids and to take or give oral solution only with included dosing device.

• Make sure patient or caregiver understands dose escalation.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


A trademark for the drug memantine hydrochloride.


a trademark for memantine.


An NMDA (N-methyl D-aspartate) receptor antagonist that counters the toxic effects of glutamate excess to manage the symptoms of moderate to severe Alzheimer’s disease.

Adverse effects
Hallucinations, confusion, dizziness, headache, hypertonia, nausea, vomiting, constipation, hypertonia, cystitis, increased libido.
Proposed mechanism
Interferes with homocysteine binding at the NMDA receptor; homocysteine also mediates excitotoxicity, and disturbs glutamatergic neurotransmission.
Mentioned in ?
References in periodicals archive ?
The clinical course is also very different, as well as treatment modalities including treatment with Cholinesterase inhibitor Aricept and glutamatergic agent Namenda for the logopenic Alzheimer's disease as it still belongs to the same family of Alzheimer's disease.
And the Namenda opinion, addressed in the final section, understood the regulatory regime in the context of hard switches, but overemphasized the distinction between hard and soft switches and introduced a new, underinclusive framework based on coercion.
7) In January 2004, Actavis began to market Namenda IR, a twice-daily pill that was the first drug of its kind to treat moderate to severe Alzheimer's.
In addition, Namenda XR has benefits over earlier drugs.
For example, last February, before its patent expired on Namenda, its widely used drug to treat Alzheimer's, Forest Laboratories announced it would stop selling the existing tablet form of it in favor of new extended-release capsules called Namenda XR.
NYSE:FRX), has made plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.
Actavis will add the Alzheimer's disease treatment Namenda and newer drugs like the antidepressant Viibryd to its product portfolio with the latest in a string of multibillion-dollar acquisitions that have swelled the drugmaker's size in recent years.
The "cognitive enhancers" used by patients were Aricept, Namenda, Exelon, and Reminyl, drugs that have been approved for treating patients diagnosed with Alzheimer's disease and other forms of dementia.
Several drugs such as Namenda and Aricept that work for people with Alzheimer's have been tested without success in people with MS.
Memantine, sold under the brand name Namenda, works by binding to certain brain cell receptors in order to block the activity of the neurotransmitter glutamate, which has been shown to kill nerve cells at high levels.
Current therapies for the disease, including Namenda from Forest Laboratories Inc.
KgaA, and Merz Pharmaceuticals GmbH have filed a second lawsuit in the United States District Court for the District of Delaware against additional companies for infringement of United States Patent 5,061,703 (the '703 patent), which relates to Forest's Namenda product.